Objective of the study is to compare the efficacy of tamoxifen alone \& tamoxifen with antioxidant on semen quality of infertile male with abnormal parameters (sperm count, motility, vitality, morphology) .Infertility is defines as inability to conceive after one year of unprotected and regular intercourse. Infertility is the most important issue in the married couples and is one of the major clinical problem affecting people medically and psychologically .It affects about 5.8 to 44.2 % couples in the developing countries. Male infertility contributes to about 50% of the overall infertility. Antiestrogens are considered as one of the old and most commonly prescribed treatment of idiopathic infertility.Many studies has shown that it improves idiopathic oligozoospermia, count, motility and vitality. Spermatozoa are also prone to oxidative damage. Men who have high reactive oxygen species(ROS) may have lower fertility potential as compared to men with low ROS. High levels of ROS in semen have been correlated with reduced sperm motility and damage to sperm nuclear DNA. High levels of cytokines in the semen is correlated with sperm injury like cell membrane lipid peroxidation in the presence of raised IL-6 .Antioxidents are the most important form of protection for spermatozoa against ROS. So oral antioxidents are commonly prescribed to males with idiopathic abnormal semen parameters and infertility to reduce the oxidative stress and improves infertility. It is a single blinded randomized control trial to be conducted in Sharif Medical and Dental college, Lahore with sampling technique of probability randomized consecutive sampling technique. 110 male patients with idiopathic male infertility and abnormal semen parameters will be recruited . Pre treatment semen analysis and LH, FSH and serum testosterone will be done. 55 patients will be given tamoxifen alone ad 55 patients will be given tamoxifen with antioxidant. Then at the interval of 3 and 6 months after treatment , semen analysis and hormonal profile will be repeated. Pre-treatment and post treatment semen parameters will be compared using paired sample t-test. P-value \< 0.05 will be taken as significant.
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Semen Volume
Timeframe: at 3 months posttreatment
Semen Volume
Timeframe: at 6 months posttreatment
Total sperm Count
Timeframe: 3 months posttreatment
Total sperm Count
Timeframe: 6 months posttreatment
Sperm concentration
Timeframe: 3 months posttreatment
Sperm concentration
Timeframe: 6 months posttreatment
Progressive motility
Timeframe: 3 months posttreatment.
Progressive motility
Timeframe: 6 months posttreatment
Sperm Morphology:
Timeframe: 3 months posttreatment
Sperm Morphology:
Timeframe: 6 months posttreatment
Vitality
Timeframe: 3 months posttreatment
Vitality
Timeframe: 6 months posttreatment
Leutinizing hormone
Timeframe: 3 months posttreatment
Leutinizing hormone
Timeframe: 6 months posttreatment
Follicular stimulating hormone
Timeframe: 3 months posttreatment.
Follicular stimulating hormone
Timeframe: 6 months posttreatment.
Serum Testosterone
Timeframe: 3 months posttreatment.
Serum Testosterone
Timeframe: 6 months posttreatment.